Sonoma Pharmaceuticals In... (SNOA)
Sonoma Pharmaceuticals Statistics
Share Statistics
Sonoma Pharmaceuticals has 1.62M shares outstanding. The number of shares has increased by -91.5% in one year.
| Shares Outstanding | 1.62M |
| Shares Change (YoY) | -91.5% |
| Shares Change (QoQ) | 20.65% |
| Owned by Institutions (%) | 2.79% |
| Shares Floating | 1.59M |
| Failed to Deliver (FTD) Shares | 198.94K |
| FTD / Avg. Volume | 12.54% |
Short Selling Information
The latest short interest is 79.9K, so 5.97% of the outstanding shares have been sold short.
| Short Interest | 79.9K |
| Short % of Shares Out | 5.97% |
| Short % of Float | 6.06% |
| Short Ratio (days to cover) | 0.22 |
Valuation Ratios
The PE ratio is -0.58 and the forward PE ratio is -2.28. Sonoma Pharmaceuticals's PEG ratio is 0.01.
| PE Ratio | -0.58 |
| Forward PE | -2.28 |
| PS Ratio | 0.22 |
| Forward PS | 0.2 |
| PB Ratio | 0.45 |
| P/FCF Ratio | -1.15 |
| PEG Ratio | 0.01 |
Enterprise Valuation
Currently the Enterprise Value (EV) is not available for Sonoma Pharmaceuticals.
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 3.37, with a Debt / Equity ratio of 0.1.
| Current Ratio | 3.37 |
| Quick Ratio | 2.64 |
| Debt / Equity | 0.1 |
| Debt / EBITDA | -0.13 |
| Debt / FCF | -0.25 |
| Interest Coverage | 0 |
Financial Efficiency
Return on Equity is n/a and Return on Invested Capital is n/a.
| Return on Equity | n/a |
| Return on Assets | n/a |
| Return on Invested Capital | n/a |
| Revenue Per Employee | $1.27M |
| Profits Per Employee | $-483.5K |
| Employee Count | 10 |
| Asset Turnover | 0.86 |
| Inventory Turnover | 2.94 |
Taxes
| Income Tax | -196K |
| Effective Tax Rate | 3.9% |
Stock Price Statistics
The stock price has increased by -31.01% in the last 52 weeks. The beta is 1.56, so Sonoma Pharmaceuticals's price volatility has been higher than the market average.
| Beta | 1.56 |
| 52-Week Price Change | -31.01% |
| 50-Day Moving Average | 2.7 |
| 200-Day Moving Average | 3.56 |
| Relative Strength Index (RSI) | 37.53 |
| Average Volume (20 Days) | 1.59M |
Income Statement
In the last 12 months, Sonoma Pharmaceuticals had revenue of 12.73M and earned -4.83M in profits. Earnings per share was -5.32.
| Revenue | 12.73M |
| Gross Profit | 4.75M |
| Operating Income | -4.7M |
| Net Income | -4.83M |
| EBITDA | -4.53M |
| EBIT | -4.7M |
| Earnings Per Share (EPS) | -5.32 |
Balance Sheet
The company has 3.13M in cash and 608K in debt, giving a net cash position of 2.52M.
| Cash & Cash Equivalents | 3.13M |
| Total Debt | 608K |
| Net Cash | 2.52M |
| Retained Earnings | -194.35M |
| Total Assets | 13.67M |
| Working Capital | 8.68M |
Cash Flow
In the last 12 months, operating cash flow was -2.4M and capital expenditures -17K, giving a free cash flow of -2.42M.
| Operating Cash Flow | -2.4M |
| Capital Expenditures | -17K |
| Free Cash Flow | -2.42M |
| FCF Per Share | -2.66 |
Margins
Gross margin is 37.26%, with operating and profit margins of -36.91% and -37.97%.
| Gross Margin | 37.26% |
| Operating Margin | -36.91% |
| Pretax Margin | -39.51% |
| Profit Margin | -37.97% |
| EBITDA Margin | -35.53% |
| EBIT Margin | -36.91% |
| FCF Margin | -18.96% |
Dividends & Yields
SNOA does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | n/a |
| FCF Yield | n/a |
Analyst Forecast
Currently there are no analyst rating for SNOA.
| Price Target | n/a |
| Price Target Difference | n/a |
| Analyst Consensus | n/a |
| Analyst Count | n/a |
Stock Splits
The last stock split was on Aug 30, 2024. It was a backward split with a ratio of 1:20.
| Last Split Date | Aug 30, 2024 |
| Split Type | backward |
| Split Ratio | 1:20 |
Scores
| Altman Z-Score | -19.24 |
| Piotroski F-Score | 3 |